[The significance of dynamic detection of WT1 expression on patients of hematologic malignancy following allogeneic hematopoietic stem cell transplantation].
To evaluate preliminarily the significance of dynamic detection of Wilms' tumor gene (WT1) expression level on monitoring minimal residual disease (MRD) and predicting clinical relapse in patients of malignancy following allogeneic hematopoietic stem cell transplantation (allo-HSCT). WT1 expression level was measured with real-time quantitative reverse transcription polymerase chain reaction (RQ-RT-PCR) method on 102 bone marrow specimens from 31 patients following allo-HSCT. WT1 expression level was determined as the ratio of WT1 mRNA to ABL mRNA times 100%. The levels of WT1 expression showed significant difference between the relapsed group and the non-relapsed group (P < 0.01), with 0.80% and 0.17% as their median expression level respectively. After dynamic measuring WT1 expression level on patients in the relapsed group, the level was found to increase significantly as compared with those during or before the clinical hematological relapse, both being > 1.0%. The level at the time of relapse was significantly higher than the latest previous one (P < 0.05). Dynamic detection of WT1 expression level with RQ-RT-PCR may be of help in monitoring MRD and warning clinical relapse on the patients following allo-HSCT.